Literature DB >> 29293157

CD32 Expression of Different Memory T Cell Subpopulations in the Blood and Lymph Nodal Tissue of HIV Patients and Healthy Controls Correlates With Immune Activation.

Melanie Wittner1,2, Gábor A Dunay, Silke Kummer1,2, Maximillian Bockhorn3, Anja Hüfner1, Stefan Schmiedel1, Olaf Degen1,2, Jan van Lunzen1,2,4, Johanna M Eberhard1,2, Julian Schulze Zur Wiesch1,2.   

Abstract

BACKGROUND: Recently, CD32 has been described to be a specific surface marker of latently HIV-infected CD4 T cells, but little is known about the frequency and distribution of CD32 expression on naive and memory CD8 and CD4 T cell populations in HIV patients and healthy individuals.
METHODS: We studied peripheral blood samples of 36 HIV-1-infected patients [23 viremic patients / 13 antiretroviral therapy(ART)-treated] and healthy individuals (n = 14) as well as cells from lymph nodes (8 HIV infected, 5 controls) using a multiparametric flow cytometry panel determining surface expression of CD3, CD8, CD4, CD45RA, CCR7, CD27, CD25, CD127, CCR5, CCR6, CXCR4, CD38, HLA-DR, TIGIT, and PD-1.
RESULTS: Overall, expression of CD32 on total peripheral CD4 T cells between viremic HIV patients, ART-treated and healthy individuals only slightly differed (mean values 1.501%, 0.2785%, and 0.2343%, respectively). However, the level of expression was significantly higher in peripheral and lymph nodal memory CD4 T cell subpopulations of viremic patients compared with ART-treated patients and healthy controls. CD32 CD4 T cells showed higher immune activation and higher expression of CXCR4 than their CD32 counterparts. Furthermore, expression of CD32 on total CD4 T cells and memory T cell populations correlated with general immune activation regardless of the infection status.
CONCLUSIONS: Follow-up studies will have to further evaluate CD32 as marker of latently HIV-infected CD4 T cells since other host-related variables such as immune activation seem to influence CD32 expression regardless of the infection status.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29293157     DOI: 10.1097/QAI.0000000000001622

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  11 in total

1.  The Latent Human Immunodeficiency Virus (HIV) Reservoir Resides Primarily in CD32-CD4+ T Cells in Perinatally HIV-Infected Adolescents With Long-Term Virologic Suppression.

Authors:  Adit Dhummakupt; Lilly V Siems; Dolly Singh; Ya Hui Chen; Thuy Anderson; Aleisha Collinson-Streng; Hao Zhang; Purvish Patel; Allison Agwu; Deborah Persaud
Journal:  J Infect Dis       Date:  2019-01-01       Impact factor: 5.226

2.  CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells.

Authors:  Mohamed Abdel-Mohsen; Leticia Kuri-Cervantes; Judith Grau-Exposito; Adam M Spivak; Racheal A Nell; Costin Tomescu; Surya Kumari Vadrevu; Leila B Giron; Carla Serra-Peinado; Meritxell Genescà; Josep Castellví; Guoxin Wu; Perla M Del Rio Estrada; Mauricio González-Navarro; Kenneth Lynn; Colin T King; Sai Vemula; Kara Cox; Yanmin Wan; Qingsheng Li; Karam Mounzer; Jay Kostman; Ian Frank; Mirko Paiardini; Daria Hazuda; Gustavo Reyes-Terán; Douglas Richman; Bonnie Howell; Pablo Tebas; Javier Martinez-Picado; Vicente Planelles; Maria J Buzon; Michael R Betts; Luis J Montaner
Journal:  Sci Transl Med       Date:  2018-04-18       Impact factor: 17.956

Review 3.  The Contributions of Clinical Pharmacology to HIV Cure Research.

Authors:  Courtney V Fletcher; Shetty Ravi Dyavar; Arpan Acharya; Siddappa N Byrareddy
Journal:  Clin Pharmacol Ther       Date:  2021-04-18       Impact factor: 6.903

4.  Mass Cytometry Analysis Reveals the Landscape and Dynamics of CD32a+ CD4+ T Cells From Early HIV Infection to Effective cART.

Authors:  Sixtine Coindre; Nicolas Tchitchek; Lamine Alaoui; Bruno Vaslin; Christine Bourgeois; Cecile Goujard; Veronique Avettand-Fenoel; Camille Lecuroux; Pierre Bruhns; Roger Le Grand; Anne-Sophie Beignon; Olivier Lambotte; Benoit Favier
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

5.  CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA.

Authors:  Genevieve E Martin; Matthew Pace; John P Thornhill; Chansavath Phetsouphanh; Jodi Meyerowitz; Morgane Gossez; Helen Brown; Natalia Olejniczak; Julianne Lwanga; Gita Ramjee; Pontiano Kaleebu; Kholoud Porter; Christian B Willberg; Paul Klenerman; Nneka Nwokolo; Julie Fox; Sarah Fidler; John Frater
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

Review 6.  The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like.

Authors:  Gilles Darcis; Ben Berkhout; Alexander O Pasternak
Journal:  Front Immunol       Date:  2019-09-20       Impact factor: 7.561

7.  CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir.

Authors:  Roger Badia; Ester Ballana; Marc Castellví; Edurne García-Vidal; Maria Pujantell; Bonaventura Clotet; Julia G Prado; Jordi Puig; Miguel A Martínez; Eva Riveira-Muñoz; José A Esté
Journal:  Nat Commun       Date:  2018-07-16       Impact factor: 14.919

8.  In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells.

Authors:  Amanda G Tomalka; Ivelisse Resto-Garay; Kerry S Campbell; Daniel L Popkin
Journal:  Front Immunol       Date:  2018-11-05       Impact factor: 7.561

9.  HIV persistence in mucosal CD4+ T cells within the lungs of adults receiving long-term suppressive antiretroviral therapy.

Authors:  Cecilia T Costiniuk; Syim Salahuddin; Omar Farnos; Ron Olivenstein; Amélie Pagliuzza; Marianna Orlova; Erwin Schurr; Christina De Castro; Jean Bourbeau; Jean-Pierre Routy; Petronela Ancuta; Nicolas Chomont; Mohammad-Ali Jenabian
Journal:  AIDS       Date:  2018-10-23       Impact factor: 4.177

10.  CD32 Expression is not Associated to HIV-DNA content in CD4 cell subsets of individuals with Different Levels of HIV Control.

Authors:  Marcial García; María Angeles Navarrete-Muñoz; José M Ligos; Alfonso Cabello; Clara Restrepo; Juan Carlos López-Bernaldo; Francisco Javier de la Hera; Carlos Barros; María Montoya; Manuel Fernández-Guerrero; Vicente Estrada; Miguel Górgolas; José M Benito; Norma Rallón
Journal:  Sci Rep       Date:  2018-10-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.